Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S | Q13698 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921748 | 0.95 | TMEM97 (0.34) | CACNA1STMEM97SIGMAR1TP53MMP9 | |
| SCHEMBL2922473 | 0.92 | TMEM97 (0.35) | CACNA1STMEM97SIGMAR1TP53MMP9 | |
| SCHEMBL2917220 | 0.92 | CACNA1S (0.32) | CACNA1STMEM97SIGMAR1 | |
| SCHEMBL2921446 | 0.91 | MAPT (0.31) | CACNA1S | |
| SCHEMBL2916830 | 0.91 | MEN1 (0.33) | CACNA1STP53TACR1 | |
| SCHEMBL2925215 | 0.90 | TP53 (0.37) | CACNA1STMEM97SIGMAR1TP53MMP9 | |
| SCHEMBL2925718 | 0.90 | TMEM97 (0.33) | CACNA1STMEM97SIGMAR1TP53MMP9 | |
| SCHEMBL2923072 | 0.90 | TP53 (0.35) | CACNA1STMEM97SIGMAR1TP53MMP9 | |
| SCHEMBL2922840 | 0.89 | TMEM97 (0.35) | CACNA1STMEM97SIGMAR1TP53MMP9 | |
| SCHEMBL2924683 | 0.89 | MAPT (0.38) | TMEM97SIGMAR1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1958634-A2 | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080171748-A1 | Substituted piperidines | NOVARTIS AG (CH) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | CACNA1S 849/4885TMEM97 3298/4885SIGMAR1 1382/4885 |
| US-20080171748-A1 | Substituted piperidines | REN, ACE, AGTR2 | CACNA1S 587/4885TMEM97 2537/4885SIGMAR1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.